Reasons to Hold Veeva Systems Stock in Your Portfolio for Now

Veeva Systems reported Q2 fiscal 2026 revenue of $789M (+16.7% YoY), beating guidance, with a trailing four-quarter earnings surprise of 9.7%. The company is also advancing its AI rollout (agentic AI via Veeva AI, with initial CRM/commercial releases in December and broader clinical/regulatory expansion through 2027) and is seeing strong adoption momentum through Vault CRM, including enterprise wins from top pharma. Offsetting this, costs are rising: G&A increased 56.1% YoY in Q2 and the company expects higher sales/marketing and overall operating expenses in fiscal 2026 due to headcount growth. Zacks consensus estimates for FY2026 EPS rose by $0.15 to $7.68 (+15 cents) over the past 60 days, supporting a mildly positive outlook despite near-term cost headwinds.

Analysis

VEEV is behaving less like a single-product SaaS story and more like a control point in the pharma operating stack. The important second-order effect is that integration wins and workflow standardization raise switching costs across adjacent modules; once CRM lands, expansion into clinical, quality, and regulatory functions becomes materially cheaper, which should support multi-year net retention even if headline growth normalizes.

Near term, the main risk is that the market underweights the cost ramp. Higher hiring and compensation can suppress operating leverage for several quarters, so the stock may need continued estimate revisions to justify further multiple expansion. If subscription growth stays high but margins flatten, the right holder base shifts from growth-at-any-price funds to quality compounders, which can cap upside after a strong YTD move.

The contrarian view is that consensus may be too focused on this quarter's beat and not enough on platform adoption durability. The real competitive loser is the legacy stack around Salesforce-based pharma workflows, while IQVIA looks more like a distribution partner than a pure competitor; that dynamic should reinforce Veeva's ecosystem moat rather than commoditize it. The thesis breaks if operating expense growth continues to outrun revenue growth or if AI functionality fails to convert into measurable module expansion over the next 2-4 quarters.

Key Decisions for Investors

• Stay constructive on VEEV, but prefer buying on a 5-8% pullback rather than chasing strength; the setup is better for a 6-12 month compounder than a near-term momentum trade.
• For accounts that want defined risk, use a 6-9 month VEEV call spread financed with a farther OTM call sale; the trade works if estimate revisions keep drifting higher, but limits damage if margin concerns re-rate the stock.
• Watch FY26 operating expense trajectory as the key falsifier: if opex growth remains above revenue growth for another quarter, reduce exposure because the market may stop paying for 'future leverage.'
• Relative-value idea: long VEEV vs. a legacy software basket/IGV as a hedge against broad SaaS multiple compression; the company-specific adoption story is stronger than the sector average.
• No aggressive long IQV here despite the partnership headline; treat IQVIA as a partner-enabler, not a clean beneficiary, unless the next data point shows incremental data monetization or accretive cross-sell.